05 July 2020: Clinical Research
Suppression of Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1) Potentiates Cell Apoptosis and Drug Sensitivity to Taxanes and Adriamycin in Breast Cancer
Jie Yu 1ABCDEF , Taobo Jin 2BCDEF , Tianya Zhang 2BCEF*DOI: 10.12659/MSM.922672
Med Sci Monit 2020; 26:e922672
Table 2 The association between MALAT1 expression and clinicopathological variables in breast cancer patients.
| Variables | Case (n) | MALAT1 expression | P value | |
|---|---|---|---|---|
| Poor (n=40) | High (n=40) | |||
| Age | 0.823 | |||
| ≤65 years | 38 | 20 (50.0) | 18 (45.5) | |
| >65 years | 42 | 20 (40.0) | 22 (54.5) | |
| Tumor size | 0.999 | |||
| ≤3 cm | 33 | 16 (40.0) | 17 (42.5) | |
| >3 cm | 47 | 24 (60.0) | 23 (57.5) | |
| Clinical stage | 0.012 | |||
| I+II | 34 | 11 (27.5) | 23 (57.5) | |
| III+IV | 46 | 29 (72.5) | 17 (42.5) | |
| Lymph node metastasis | ||||
| No | 48 | 32 (87.5) | 13 (32.50) | |
| Yes | 32 | 8 (12.5) | 27 (67.50) | |
| Differentiation | ||||
| Low/Median | 52 | 16 (40.0) | 36 (90.0) | |
| High | 28 | 24 (60.0) | 4 (10.0) | |
| ER | 0.027 | |||
| Positive | 56 | 33 (82.50) | 23 (57.50) | |
| Negative | 24 | 7 (17.50) | 17 (42.50) | |
| PR | ||||
| Positive | 47 | 33 (82.50) | 14 (35.00) | |
| Negative | 33 | 7 (17.50) | 26 (65.00) | |
| HER | 0.034 | |||
| Positive | 52 | 31 (77.50) | 21 (52.50) | |
| Negative | 28 | 9 (22.50) | 19 (47.50) | |
| MALAT1 – metastasis-associated lung adenocarcinoma transcript 1; ER – estrogen receptor; PR – progesterone receptor; HER-2 – human epidermal growth factor receptor 2. | ||||